ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has suspended registration of three drug products that do not qualify the criteria of safety, efficacy and quality (SEQ).
The suspended drug products include painkiller tablets of Diclofenac Potassium in strengths of 75 and 100 mg, liquid suspension of anti-ulcer drug Famotidine in strengths of 10mg/5ml and 40mg/5ml, and a combination drug product containing paracetamol, thioridazine and caffeine. In a press release issued here on Saturday, DRAP has advised healthcare professionals, patients and their attendants to desist from prescribing or using these drug products as there is very less data on their SEQ.
JUI-F filed a petition through advocate Kamran Murtaza
New data from 187 countries shows that the estimated number of deaths from viral hepatitis increased from 1.1 million...
APTMA also drew the attention of the finance minister toward high taxes and persistent delays in refunds have squeezed...
The guard appeared at the Westminster Magistrates Court on Wednesday afternoon with his lawyer Moeen Khan
Ogra determines the natural gas tariff for domestic sector consumers and LNG price separately for power sector
The chief minister directed prompt completion of the Lahore Ring Road SL-3 project and urged immediate action
